Diamond Hill Capital Management LLC Investment Advisor Makes New $33.81 Million Investment in Icon Plc $ICLR

Posted by Geri Gentry on Aug 17th, 2026

Diamond Hill Capital Management LLC Investment Advisor bought a new stake in shares of Icon Plc (NASDAQ:ICLR – Free Report) during the 2nd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund bought 194,618 shares of the medical research company’s stock, valued at approximately $33,807,000.

Other hedge funds and other institutional investors also recently made changes to their positions in the company. Wellington Management Group LLP lifted its stake in Icon by 26.6% in the third quarter. Wellington Management Group LLP now owns 4,637,137 shares of the medical research company’s stock worth $811,499,000 after acquiring an additional 975,268 shares during the period. Orbis Allan Gray Ltd boosted its holdings in Icon by 1.8% in the fourth quarter. Orbis Allan Gray Ltd now owns 4,214,661 shares of the medical research company’s stock valued at $767,996,000 after acquiring an additional 75,843 shares in the last quarter. Invesco Ltd. increased its position in Icon by 9.6% during the 4th quarter. Invesco Ltd. now owns 3,756,896 shares of the medical research company’s stock valued at $684,582,000 after purchasing an additional 329,266 shares during the period. Principal Financial Group Inc. raised its holdings in Icon by 10.3% in the 1st quarter. Principal Financial Group Inc. now owns 3,311,771 shares of the medical research company’s stock worth $366,481,000 after purchasing an additional 310,236 shares in the last quarter. Finally, Franklin Resources Inc. raised its holdings in Icon by 8.7% in the 4th quarter. Franklin Resources Inc. now owns 2,993,336 shares of the medical research company’s stock worth $545,410,000 after purchasing an additional 239,808 shares in the last quarter. Institutional investors own 95.61% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have recently weighed in on ICLR. JPMorgan Chase & Co. lifted their target price on shares of Icon from $130.00 to $155.00 and gave the company a “neutral” rating in a research note on Thursday, June 25th. Leerink Partners set a $145.00 price target on shares of Icon in a research note on Thursday, May 28th. Weiss Ratings lowered shares of Icon from a “sell (d+)” rating to a “sell (d)” rating in a report on Friday, May 29th. William Blair raised Icon to a “strong-buy” rating in a research report on Thursday, July 30th. Finally, Piper Sandler downgraded Icon to a “neutral” rating in a report on Thursday, May 28th. One research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating, seven have issued a Hold rating and two have issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $170.40.

Get Our Latest Stock Analysis on ICLR

Icon Price Performance

ICLR stock opened at $163.15 on Monday. Icon Plc has a 1-year low of $66.57 and a 1-year high of $203.91. The business has a fifty day moving average price of $162.50 and a 200-day moving average price of $133.87. The company has a debt-to-equity ratio of 0.23, a current ratio of 0.95 and a quick ratio of 0.95. The stock has a market capitalization of $12.49 billion, a P/E ratio of 38.30, a P/E/G ratio of 6.76 and a beta of 1.21.

Icon (NASDAQ:ICLR – Get Free Report) last released its quarterly earnings data on Thursday, July 30th. The medical research company reported $2.56 EPS for the quarter, beating the consensus estimate of $2.55 by $0.01. Icon had a return on equity of 8.02% and a net margin of 3.99%.The company had revenue of $2.06 billion for the quarter, compared to analysts’ expectations of $2 billion. During the same period last year, the firm posted $3.26 earnings per share. Icon’s revenue was up 2.3% compared to the same quarter last year. Equities analysts forecast that Icon Plc will post 9.57 earnings per share for the current fiscal year.

Insider Buying and Selling at Icon

In other Icon news, CFO Nigel Bernard John Clerkin sold 2,267 shares of the company’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $164.29, for a total transaction of $372,445.43. Following the transaction, the chief financial officer owned 5,881 shares in the company, valued at approximately $966,189.49. This represents a 27.82% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, Director Ronan Martin Murphy sold 841 shares of the firm’s stock in a transaction dated Tuesday, August 11th. The shares were sold at an average price of $164.29, for a total transaction of $138,167.89. Following the sale, the director directly owned 3,847 shares in the company, valued at approximately $632,023.63. The trade was a 17.94% decrease in their position. The SEC filing for this sale provides additional information. The sale was made to cover tax withholding obligations related to the vesting of equity awards. In the last ninety days, insiders have sold 9,531 shares of company stock worth $1,565,764. 44.00% of the stock is owned by company insiders.

Icon Profile

(Free Report)

Icon plc (NASDAQ: ICLR) is a global provider of outsourced drug development and clinical research services to the pharmaceutical, biotechnology and medical device industries. The company partners with clients at all stages of the product life cycle, offering expertise in protocol design, trial execution and regulatory compliance across a broad range of therapeutic areas.

Icon’s service portfolio encompasses clinical trial management, data management and biostatistics, medical imaging, pharmacovigilance and safety monitoring, laboratory sciences and specialized analytical solutions.